Japan Approves First Stem-Cell Therapy for Parkinson’s Disease

 



Japan has approved a groundbreaking stem-cell therapy for Parkinson’s disease, marking a major milestone in regenerative medicine. The Japanese government also cleared a similar treatment for severe heart failure, potentially making them the world’s first commercially available medical products based on induced pluripotent stem (iPS) cells. The therapies are expected to reach patients within months, reflecting Japan’s growing leadership in advanced biomedical innovation.

Parkinson’s Therapy Using Stem Cells

Japanese pharmaceutical company Sumitomo Pharma received approval to manufacture and market a Parkinson’s treatment called Amchepry. The therapy involves transplanting laboratory-grown stem cells directly into a patient’s brain.

These stem cells are developed into precursors of dopamine-producing neurons. In Parkinson’s disease, these neurons gradually deteriorate, leading to symptoms such as tremors, stiffness, and difficulty in movement. By replacing these damaged cells, the treatment aims to restore dopamine production and improve motor functions.

The approval was granted under a conditional and time-limited framework designed to accelerate access to innovative therapies while continuing to monitor their long-term effectiveness.

Clinical Trial Results and Patient Outcomes

The treatment was tested in a clinical study led by researchers from Kyoto University. The trial involved seven Parkinson’s patients aged between 50 and 69 years. Each patient received either five million or ten million stem-cell-derived neurons implanted into both sides of the brain.


Patients were monitored for two years following the procedure. The study found no major adverse effects, demonstrating the safety of the therapy. Four of the participants showed noticeable improvement in their symptoms, suggesting that stem-cell-based interventions could become a promising approach to managing neurodegenerative diseases.

Stem Cells and the iPS Breakthrough

The therapy is based on induced pluripotent stem cells, commonly known as iPS cells. These cells are created by reprogramming mature adult cells back into a primitive state, allowing them to develop into many different types of human cells.

Japanese scientist Shinya Yamanaka pioneered this technology and received the Nobel Prize in Physiology or Medicine in 2012 for the discovery. iPS cells offer an ethical and scientific advantage because they do not require the use of embryos and can be produced from donor cells.

Heart Failure Treatment Also Cleared

Japan’s health ministry also approved a second regenerative therapy called ReHeart, developed by medical startup Cuorips. The treatment uses sheets of heart muscle cells derived from stem cells and placed on the heart’s surface.

#StemCells
#StemCellResearch
#RegenerativeMedicine
#CellTherapy
#TissueEngineering
#StemCellBiology
#BiomedicalResearch
#CellRegeneration
#MedicalInnovation
#Biotechnology


World Cell Biologist Awards: 

Website Link : cellbiologist.org 

Follow Us On : 
Tumblr ; tumblr.ccom/

Comments

Post a Comment

Popular posts from this blog

Uttrakhand Forest Department Establishes Mahabharata Vatika

Image
  The Uttarakhand Forest Department has established two gardens in Haldwani, showcasing plant species referenced in ancient Indian epics. These gardens, named Ramayana Vatika and Mahabharata Vatika, aim to highlight the ecological wisdom embedded in these texts. Mahabharata Vatika Overview Mahabharata Vatika spans one acre and features 37 plant species mentioned in the epic. Chief Conservator of Forests Sanjeev Chaturvedi emphasised the research behind selecting these species. The garden features important plant species such as: Ecological Significance The garden puts stress on the importance of forests as depicted in the Mahabharata. It references the Vana Parva, which discusses tree planting and wildlife conservation . The epic highlights the mutual dependence of tigers and forests, a concept vital to contemporary conservation efforts. Cultural Connections Chaturvedi brought into light that the Mahabharata teaches the spiritual significance of planting trees. He mentioned Bhish...
Read more

CAR T-Cell Therapy for Cancer

Image
  India has recently made strides in cancer treatment with the introduction of CAR T-cell therapy . The results from the first clinical trials have been published in The Lancet, showcasing a remarkable success rate. This therapy is a game changer for patients with blood cancers. It offers hope to those who have exhausted other treatment options. What is CAR T-Cell Therapy? CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, is an innovative treatment that harnesses the body’s immune system. It trains T-cells to target and destroy cancer cells. This therapy is specifically designed for certain blood cancers. It is particularly beneficial for patients whose cancer has relapsed or failed to respond to standard treatments. Clinical Trial The clinical trials reported a response rate of nearly 73%. This indicates that number of patients benefited from the treatment. The trials also provided critical data on survival rates for patients with acute lymphoblastic leukaemia and l...
Read more

What is Zolgensma?

Image
  Spinal Muscular Atrophy (SMA) is a rare genetic disease affecting muscle function. In India, treatment options are limited, mainly due to high costs. The gene therapy drug, Zolgensma , costs around 16 crore rupees. Despite this, some families are finding ways to access treatment. About Spinal Muscular Atrophy (SMA) SMA is a genetic disorder that leads to the loss of motor neurons in the spinal cord. This results in muscle weakness and atrophy. Symptoms often appear in infancy. Children may struggle with basic movements like lifting their heads or crawling. Early diagnosis is crucial for effective treatment. About Zolgensma Zolgensma (onasemnogene abeparvovec-xioi) is a revolutionary gene therapy for SMA. It addresses the root cause by replacing the missing or defective SMN1 gene . This therapy can improve motor function in affected children. Although it is costly, it represents hope for many families. SMA is not as rare as once thought. The global prevalence is estimated at 1 in ...
Read more